Stock AnalizPfizer Inc. PFE
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Pfizer Inc. (PFE) is a healthcare company listed in the US with a market value of about $164.7B. In the twelve months to September 27, 2026 it had revenue of $63.6B and net income of $4.0B, a net margin of 6.3%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (1/5).
Key numbers: a P/E of 41.3, a price to free cash flow of 14.0, 5-year revenue growth of 8% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% below the current price.
Score: 2.2 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- Positive free cash flow
- Liabilities below 60% of assets
- Pays a dividend
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.6B | $62.6B | $63.6B | $59.6B | $101.2B | $81.3B | $41.7B | $40.9B | $40.8B | $52.5B | $52.8B |
| Net income | $4.0B | $7.8B | $8.0B | $2.1B | $31.4B | $22.0B | $9.2B | $16.0B | $11.2B | $21.3B | $7.2B |
| Free cash flow | $11.8B | $9.1B | $9.8B | $4.8B | $26.0B | $29.9B | $12.2B | $10.5B | $13.8B | $14.8B | $14.4B |
| EPS (diluted) | $0.70 | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 | $3.52 | $1.17 |
| Net margin | 6.3% | 12.4% | 12.6% | 3.6% | 31.0% | 27.0% | 22.0% | 39.2% | 27.3% | 40.6% | 13.7% |
| ROIC | — | 5.2% | 5.8% | 1.7% | 24.2% | 20.1% | 7.7% | 12.0% | 3.8% | 9.9% | 8.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 26 analysts is $30.22, 5% above the current price; targets range from $25.00 to $37.00; the consensus rating is “Buy”; expected EPS is $3.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Pfizer’s P/E ratio?
About 41.3, based on the last twelve months of diluted earnings per share (forward P/E about 10.1).
Is Pfizer stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 30% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Pfizer pay a dividend?
Yes. The dividend yield is about 5.84%, and it has paid dividends for 10 years in our data.
Is Pfizer a good stock to buy?
We do not give buy or sell advice. Pfizer scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.